Please wait while the formulary information is being retrieved.
Drug overview for CHIRHOSTIM (secretin acetate (human)):
Generic name: SECRETIN ACETATE (HUMAN)
Drug class:
Therapeutic class: Diagnostic Agents
Secretin is a hormone secreted principally by the duodenal mucosa that is used to aid in the diagnosis of pancreatic exocrine dysfunction or gastrinoma or to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP).
Secretin is used to stimulate pancreatic secretions to aid in the diagnosis of pancreatic exocrine dysfunction or to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP). Secretin also is used to stimulate gastrin release to aide in the diagnosis of gastrinoma.
Generic name: SECRETIN ACETATE (HUMAN)
Drug class:
Therapeutic class: Diagnostic Agents
Secretin is a hormone secreted principally by the duodenal mucosa that is used to aid in the diagnosis of pancreatic exocrine dysfunction or gastrinoma or to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP).
Secretin is used to stimulate pancreatic secretions to aid in the diagnosis of pancreatic exocrine dysfunction or to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP). Secretin also is used to stimulate gastrin release to aide in the diagnosis of gastrinoma.
DRUG IMAGES
No Image Available
The following indications for CHIRHOSTIM (secretin acetate (human)) have been approved by the FDA:
Indications:
Secretin stimulation testing
Professional Synonyms:
Oxykrinin stimulation testing
Indications:
Secretin stimulation testing
Professional Synonyms:
Oxykrinin stimulation testing
The following dosing information is available for CHIRHOSTIM (secretin acetate (human)):
Dosage of synthetic porcine secretin (secretin acetate) is expressed by weight (in mcg) in terms of the base; each 0.2 mcg of synthetic porcine secretin is approximately equivalent to 1 clinical unit (CU) of biologic activity. (See Description.)
Before administration of the full dose of secretin acetate, a test dose of 0.2 mcg, administered by IV injection, should be given, followed by observation of the patient for approximately 1 minute. If no acute reaction occurs, the full dose of secretin acetate can be administered.
Before administration of the full dose of secretin acetate, a test dose of 0.2 mcg, administered by IV injection, should be given, followed by observation of the patient for approximately 1 minute. If no acute reaction occurs, the full dose of secretin acetate can be administered.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for CHIRHOSTIM (secretin acetate (human)):
There are 0 contraindications.
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Secretin/Anticholinergics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Anticholinergic drugs may result in an incorrect secretin stimulation test result.(1) CLINICAL EFFECTS: Concurrent use of anticholinergic drugs may impact the accuracy of the secretin stimulation test.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of human secretin states concurrent use of anticholinergic drugs at the time of stimulation testing may cause the patient to be hyporesponsive to the testing and suggest false positive results for pancreatic disease. The manufacturer recommends discontinuing anticholinergic drugs at least 5 half-lives prior to stimulation testing. Consider additional testing and clinical assessment for diagnosis.(1) DISCUSSION: Concurrent use of anticholinergic drugs may impact the accuracy of the secretin stimulation test.(1) |
ANASPAZ, ATROPINE SULFATE, BELLADONNA, BELLADONNA LEAF POWDER, BELLADONNA-OPIUM, BENZTROPINE MESYLATE, CHLORDIAZEPOXIDE-CLIDINIUM, CLIDINIUM BROMIDE, COBENFY, COBENFY STARTER PACK, CUVPOSA, CYCLOPENTOLATE HCL, DARIFENACIN ER, DARTISLA, DICYCLOMINE HCL, DIPHENOXYLATE-ATROPINE, DONNATAL, ED-SPAZ, FESOTERODINE FUMARATE ER, FLAVOXATE HCL, GLYCATE, GLYCOPYRROLATE, HOMATROPINE METHYLBROMIDE, HYCODAN, HYDROCODONE-HOMATROPINE MBR, HYDROMET, HYOSCYAMINE SULFATE, HYOSCYAMINE SULFATE ER, HYOSCYAMINE SULFATE SR, HYOSYNE, IPRATROPIUM BROMIDE, ISOPROPAMIDE IODIDE, LEVBID, LEVSIN, LEVSIN-SL, LIBRAX, LOMOTIL, MB CAPS, ME-NAPHOS-MB-HYO 1, METHSCOPOLAMINE BROMIDE, MOTOFEN, NULEV, OSCIMIN, OSCIMIN SL, OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE ER, OXYTROL, PHENOBARBITAL-BELLADONNA, PHENOBARBITAL-HYOSC-ATROP-SCOP, PHENOHYTRO, PROPANTHELINE BROMIDE, RESPA A.R., ROBINUL, ROBINUL FORTE, SCOPOLAMINE, SCOPOLAMINE HYDROBROMIDE, SCOPOLAMINE METHYL NITRATE, SOLIFENACIN SUCCINATE, SYMAX, SYMAX DUOTAB, SYMAX-SL, SYMAX-SR, TOLTERODINE TARTRATE, TOLTERODINE TARTRATE ER, TOVIAZ, TRANSDERM-SCOP, TRIHEXYPHENIDYL HCL, TROPICAMIDE, TROSPIUM CHLORIDE, TROSPIUM CHLORIDE ER, URELLE, URETRON D-S, URIBEL TABS, URIMAR-T, URNEVA, URO-MP, URO-SP, UROGESIC-BLUE, URYL, VESICARE, VESICARE LS |
| Secretin/H2 Antagonists; Proton Pump Inhibitors SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: H2 antagonists and proton pump inhibitors (PPIs) may result in an incorrect secretin stimulation test result.(1) CLINICAL EFFECTS: Concurrent use of H2 antagonists and proton pump inhibitors (PPIs) may impact the accuracy of the secretin stimulation test.(1) PREDISPOSING FACTORS: Patients with alcoholic or other liver disease may be hyperresponsive to stimulation with a secretin stimulation test, masking the presence of coexisting pancreatic disease. Consider additional testing and clinical assessment for diagnosis.(1) PATIENT MANAGEMENT: The US manufacturer of human secretin states concurrent use of H2 antagonists and proton pump inhibitors (PPIs) at the time of stimulation testing may cause the patient to be hyperresponsive to secretin stimulation and suggest false gastrinoma results. The manufacturer recommends discontinuing H2 antagonists at least 2 days prior to testing. The US manufacturer of vonoprazan recommends stopping vonoprazan at least 4 weeks prior to testing.(2-3) Consult prescribing information for PPIs before administering prior to a secretin stimulation test.(1) DISCUSSION: Concurrent use of H2 antagonists and proton pump inhibitors (PPIs) may impact the accuracy of the secretin stimulation test.(1) |
ACIPHEX, ACIPHEX SPRINKLE, CIMETIDINE, DEXILANT, DEXLANSOPRAZOLE DR, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE SODIUM, FAMOTIDINE, IBUPROFEN-FAMOTIDINE, KONVOMEP, LANSOPRAZOL-AMOXICIL-CLARITHRO, LANSOPRAZOLE, NAPROXEN-ESOMEPRAZOLE MAG, NEXIUM, NIZATIDINE, OMECLAMOX-PAK, OMEPRAZOLE, OMEPRAZOLE-SODIUM BICARBONATE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM-0.9% NACL, PEPCID, PREVACID, PRILOSEC, PROTONIX, PROTONIX IV, RABEPRAZOLE SODIUM, TALICIA, VIMOVO, VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, YOSPRALA |
There are 0 moderate interactions.
The following contraindication information is available for CHIRHOSTIM (secretin acetate (human)):
Drug contraindication overview.
Known hypersensitivity to secretin or any ingredient (e.g., mannitol) in the formulation. Secretin should not be used in patients with acute pancreatitis until the acute episode has subsided.
Known hypersensitivity to secretin or any ingredient (e.g., mannitol) in the formulation. Secretin should not be used in patients with acute pancreatitis until the acute episode has subsided.
There are 0 contraindications.
There are 0 severe contraindications.
There are 4 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Alcohol use disorder |
| Alcoholic fatty liver |
| Asthma |
| Disease of liver |
The following adverse reaction information is available for CHIRHOSTIM (secretin acetate (human)):
Adverse reaction overview.
Adverse effects occurring in 1% or more of patients receiving secretin include nausea, abdominal discomfort, bleeding (secondary to sphincterectomy), decreased blood pressure, flushing, diaphoresis, endoscopic perforation of pancreatic duct, upper GI bleeding (secondary to endoscopic abrasion), abdominal cramps, mild bradycardia, burning in stomach, headache, lightheadedness, transient respiratory distress, bloating, diarrhea, fever, transient low oxygen saturation, urticaria (secondary to contrast material), vomiting, fatigue, hot sensation, hunger pangs, leukocytoplastic vasculitis, numbness/tingling in extremities, pallor, abdominal rash, thready pulse, and possible seizure.
Adverse effects occurring in 1% or more of patients receiving secretin include nausea, abdominal discomfort, bleeding (secondary to sphincterectomy), decreased blood pressure, flushing, diaphoresis, endoscopic perforation of pancreatic duct, upper GI bleeding (secondary to endoscopic abrasion), abdominal cramps, mild bradycardia, burning in stomach, headache, lightheadedness, transient respiratory distress, bloating, diarrhea, fever, transient low oxygen saturation, urticaria (secondary to contrast material), vomiting, fatigue, hot sensation, hunger pangs, leukocytoplastic vasculitis, numbness/tingling in extremities, pallor, abdominal rash, thready pulse, and possible seizure.
There are 2 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Fever |
| Rare/Very Rare |
|---|
|
Hypersensitivity drug reaction |
There are 6 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Abdominal pain with cramps Nausea |
Diarrhea Dyspepsia Flushing Vomiting |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for CHIRHOSTIM (secretin acetate (human)):
Safety and efficacy of secretin acetate have not been established in children younger than 16 years of age.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category C. (See Users Guide.)
It is not known whether porcine secretin is distributed into human milk. Because many drugs are distributed into human milk, caution is advised if secretin is administered in nursing women.
No substantial differences in safety and efficacy were observed between geriatric and younger patients in clinical studies; however, the possibility that some older patients may exhibit increased sensitivity to secretin cannot be ruled out.
The following prioritized warning is available for CHIRHOSTIM (secretin acetate (human)):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for CHIRHOSTIM (secretin acetate (human))'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool